BoneSupport receives FDA market authorization for antibiotic-eluting bone graft

BoneSupport has announced FDA market authorization of the Cerament G bone graft for patients with osteomyelitis, according to a press release.
The Cerament G bone graft, which is protected by locally eluted antibiotics, is designed to facilitate bone healing and reduce the risk of reinfection and amputation, according to the release.
“The announcement from the FDA means that BoneSupport achieves the most important milestone in the company’s commercial history to date,” Emil Billbäck, CEO of BoneSupport, said in the release. “The benefits of Cerament G for patients and

BoneSupport has announced FDA market authorization of the Cerament G bone graft for patients with osteomyelitis, according to a press release.
The Cerament G bone graft, which is protected by locally eluted antibiotics, is designed to facilitate bone healing and reduce the risk of reinfection and amputation, according to the release.
“The announcement from the FDA means that BoneSupport achieves the most important milestone in the company’s commercial history to date,” Emil Billbäck, CEO of BoneSupport, said in the release. “The benefits of Cerament G for patients and